Cerus Co. (NASDAQ:CERS) Insider Chrystal Menard Sells 26,535 Shares

Cerus Co. (NASDAQ:CERS) insider Chrystal Menard sold 26,535 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.59, for a total value of $95,260.65. Following the completion of the sale, the insider now owns 7,500 shares in the company, valued at $26,925. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of CERS stock traded up $0.43 during mid-day trading on Thursday, hitting $4.47. 837,382 shares of the stock traded hands, compared to its average volume of 2,274,683. Cerus Co. has a twelve month low of $2.71 and a twelve month high of $6.64. The firm has a market cap of $624.34 million, a price-to-earnings ratio of -8.60 and a beta of 1.19. The company’s 50-day simple moving average is $4.66 and its 200-day simple moving average is $4.51. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.16 and a current ratio of 2.55.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Cerus had a negative net margin of 95.44% and a negative return on equity of 112.64%. The firm had revenue of $20.92 million for the quarter, compared to analyst estimates of $20.90 million. Analysts forecast that Cerus Co. will post -0.44 earnings per share for the current year.

Several analysts recently commented on the company. Zacks Investment Research upgraded Cerus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 18th. BidaskClub cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. BTIG Research assumed coverage on Cerus in a research report on Wednesday, February 26th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, ValuEngine upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $7.33.

Hedge funds have recently modified their holdings of the company. CVA Family Office LLC acquired a new position in shares of Cerus during the 4th quarter valued at $42,000. Great West Life Assurance Co. Can acquired a new position in shares of Cerus during the 4th quarter valued at $44,000. Exchange Traded Concepts LLC acquired a new position in shares of Cerus during the 4th quarter valued at $57,000. Virtu Financial LLC acquired a new position in shares of Cerus in the 4th quarter worth $77,000. Finally, Alpine Global Management LLC acquired a new position in shares of Cerus in the 4th quarter worth $78,000. Institutional investors own 69.56% of the company’s stock.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading: Basic Economics creates winners and losers

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.